Why Is NVO Stock Falling Pre-Market Today?

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

📰 Article Image

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. (Photo by Li Hongbo/VCG via Getty Images)

👤

Rounak Jain · Stocktwits

Published Feb 23, 2026, 9:55 AM

NVO

Novo Nordisk AS (NVO) shares fell more than 10% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.

Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.

Retail sentiment on Stocktwits around Novo Nordisk trended in the ‘extremely bearish’ territory at the time of writing.

Get updates to this story developing directly on Stocktwits.

Also See: Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.

TrendingPremarketLarge CapEquities